Related Experiment Videos
Gabapentin as treatment for hemifacial spasm
1Department of Neurological Sciences and Neurorehabilitation, University of Genoa, Italy. bandinf16@tn.village.it
European Neurology
|July 8, 1999
Summary
Gabapentin offers a promising new treatment for hemifacial spasm, a condition causing involuntary facial muscle contractions. This anticonvulsant drug demonstrated significant effectiveness with minimal side effects in a small patient group.
Area of Science:
- Neurology
- Pharmacology
Background:
- Hemifacial spasm involves involuntary unilateral facial muscle contractions, often linked to neurovascular compression of the facial nerve.
- Current treatments like baclofen, anticonvulsants, botulinum toxin, and microvascular decompression have limitations including side effects, low efficacy, or complications.
Observation:
- A study evaluated the efficacy of the novel anticonvulsant gabapentin in five patients diagnosed with hemifacial spasm.
- Patients received daily gabapentin dosages ranging from 900 to 1,600 mg.
Findings:
- Gabapentin treatment resulted in rapid and significant improvement of hemifacial spasms across all five patients.
- No remarkable adverse effects were reported during the study period.
Implications:
- Gabapentin presents a potentially effective and well-tolerated therapeutic option for managing hemifacial spasm.
- This finding suggests gabapentin may offer a favorable benefit-risk profile compared to existing treatments for hemifacial spasm.